Table 3.

Effect of ferritin concentration GWAS identified variants on breast cancer

SNPs	Chr: BP (Build 37)	Locus	Effect/other allele	Ferritin (log) (μmol/L)		Overall breast cancer		ER-positive breast cancer		ER-negative breast cancer
				Betab (SE)	P value	Betac (SE)	P value	Betac (SE)	P value	Betac (SE)	P value
rs744653	2: 190,378,750	WDR75–SLC40A1	T/C	−0.089 (0.010)	8.37E−19	−0.008 (0.009)	0.355	−0.007 (0.011)	0.500	−0.016 (0.016)	0.310
rs1800562a	6: 26,093,141	HFE	A/G	0.204 (0.016)	1.54E−38	−0.003 (0.014)	0.831	0.010 (0.016)	0.535	−0.027 (0.025)	0.288
rs1799945a	6: 26,091,179	HFE	C/G	−0.065 (0.010)	1.71E−10	−0.001 (0.009)	0.913	−0.003 (0.011)	0.804	−0.014 (0.016)	0.380
rs411988	17: 56,709,034	TEX14	A/G	−0.044 (0.007)	1.59E−10	−0.019 (0.006)	0.003	−0.014 (0.008)	0.079	−0.027 (0.012)	0.020
rs855791a	22: 37,462,936	TMPRSS6	A/G	−0.055 (0.007)	1.98E−09	−0.003 (0.006)	0.627	0.001 (0.008)	0.852	−0.013 (0.012)	0.255

^a3 SNPs used in the conservative analyses. GWAS genome-wide association studies, SNPs single nucleotide polymorphisms, Chr chromosome, BP base pair, SE standard error, ER oestrogen receptor

^bBeta units are per-allele effect estimates ferritin concentrations

^cPer-allele logarithm of the odds ratios between breast cancer cases and controls